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Background: We explored psychometric properties of the Osteoporosis Assessment Questionnaire 2.0 in terms of
reliability, validity, and responsiveness with generic, clinical, demographic, and preference-based data collected from
a population of postmenopausal women with osteoporosis.
Methods: The Multiple Outcomes of Raloxifene Evaluation study was a randomized, placebo-controlled,
multinational clinical trial evaluating efficacy and safety of raloxifene. The Osteoporosis Assessment Questionnaire
2.0, a generic quality of life measure (Nottingham Health Profile), and a preference-based measure (Health Utilities
Index) were administered at baseline and annually. Psychometric properties of the 14 Osteoporosis Assessment
Questionnaire 2.0 domains were evaluated by standard statistical techniques.
Results: This study included a subset of 1477 women from the Multiple Outcomes of Raloxifene Evaluation study
population completing the questionnaires. Mean (standard deviation) age was 68.4 (6.8) years. Prevalent vertebral
fractures were found in 70% (n =1038) of women. Internal consistency was >0.7 in 9 Osteoporosis Assessment
Questionnaire 2.0 domains. Correlations were moderate and significant for similar Osteoporosis Assessment
Questionnaire 2.0 domain scores, Nottingham Health Profile domains, and Health Utilities Index scores. All but 2
Osteoporosis Assessment Questionnaire 2.0 domains distinguished between patients with or without prevalent
vertebral fractures and detected worsening with increased number of vertebral fractures. Women with ≥1 incident
vertebral fracture generally had a greater worsening in Osteoporosis Assessment Questionnaire 2.0 scores
(excluding social activity and support of family and friends) from baseline to study endpoint compared with
women without incident vertebral fractures.
Conclusions: Most domains in the Osteoporosis Assessment Questionnaire 2.0 demonstrated robust psychometric
properties; however, several domains not showing these criteria may need to be reassessed and removed for a
potentially shorter and validated version of the Osteoporosis Assessment Questionnaire.
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Osteoporosis is a chronic disease in which bone mineral
density (BMD) is reduced and structural deterioration of
the bone tissue occurs, which leads to bone weakness and
an increased susceptibility to fractures [1,2]. In postmeno-
pausal women, osteoporosis is the major underlying cause
of fractures, which often occur in the hip, spine, and wrist
[1-4]. Health-related quality of life (HRQoL) is a multidi-
mensional concept that defines a person’s health status in
specific dimensions including physical, social, emotional,
and functional well-being [5]. Osteoporosis also can im-
pact multiple dimensions of HRQoL, including: anxiety
and depression, reduced self-image, limitations in the abil-
ity to work and enjoy leisure activities, acute or chronic
pain, difficulties in performing the activities of daily life,
loss of independence, and changes in relationships with
family and friends [3,6]. In women with established post-
menopausal osteoporosis, vertebral fractures may result in
back pain, physical functioning limitations, and psycho-
social impairment [7,8].
Assessment of HRQoL in women with osteoporosis
remains an important objective, especially among those
women with severe osteoporosis (especially those with frac-
ture). Despite recent progress in the treatment of osteopor-
osis (e.g. more treatment options are available), there has
been limited progress in the development of osteoporosis-
specific quality of life instruments over the last decade. The
HRQoL among patients with osteoporosis—as measured
by disease-targeted instruments such as the Osteoporosis
Assessment Questionnaire (OPAQ)—decreases following
incident clinical fracture [6]. The OPAQ is an 81-item, vali-
dated instrument that was developed with patients and
healthcare professionals which shows adequate psychomet-
ric properties and appropriateness for use during clinical
trials [9-11]. Some items from the OPAQ that did not
discriminate between patients with and without prevalent
vertebral fracture in the Sanofi tiludronate trial were subse-
quently eliminated to create a short-form, 67-item OPAQ
instrument version 2.0 (OPAQ 2.0) [12]. The recall period
was also changed from 4 to 2 weeks to improve accuracy of
recall. The OPAQ 2.0 is a disease-targeted, patient-reported
measure of HRQoL in patients with osteoporosis. The
questionnaire was 1 of 2 disease-targeted instruments ad-
ministered to measure HRQoL in the Multiple Outcomes
of Raloxifene Evaluation (MORE) study.
The MORE study was the first large interventional
trial in osteoporosis to perform prospective HRQoL as-
sessments over a 3-year period [6,13-15]. While the pri-
mary objective of the MORE study was to examine the
long-term effects of raloxifene on the skeleton in post-
menopausal women with osteoporosis, the secondary
objective was to compare treatment-related changes in
HRQoL. The MORE study design and results have been
reported elsewhere; in summary, both prevalent andincident vertebral fractures were associated with de-
creases in HRQoL, and increasing numbers of prevalent
vertebral fractures were associated with progressive de-
creases in HRQoL [6,14]. According to the study results,
the HRQoL effect of vertebral fracture depends on the
number and location of fractures [6,10,14].
The validity and clinical relevance of HRQoL instru-
ments have come under increased scrutiny since the 2005
European Medical Agency and 2009 United States Food
and Drug Administration guidelines related to the use of
patient-reported outcomes (PRO) in clinical medical prod-
uct development [16,17]. These guidelines clearly specify a
need to develop and confirm the suitability of HRQoL in-
struments in the patient population for which the therapy
will be indicated in order to support the validity of eva-
luation. The HRQoL data from the MORE trial remain a
robust and rich source of HRQoL information in osteo-
porosis clinical trials. The MORE trial participants were
generally in the early stage of osteoporosis, although
MORE also included a sizable number of patients with se-
vere osteoporosis who were administered questionnaires
including the OPAQ 2.0. Therefore, the main objective of
this study was to explore the psychometric properties of
the OPAQ in terms of reliability, construct validity, and re-
sponsiveness by using PRO, clinical (e.g. fracture), demo-
graphic (e.g. age), and preference-based data collected
from women in the MORE study.
Methods
Study population
This was a post hoc retrospective analysis that used data
from the MORE study. The MORE study was a random-
ized, placebo-controlled, multinational clinical trial de-
signed to evaluate the efficacy and safety of raloxifene.
Participants in the MORE study included 7705 postmen-
opausal women, aged ≤80 years at 180 centers in 25
countries. Women, who had osteoporosis, as defined by
low BMD (T-score ≤ −2.5 standard deviations below the
young adult peak mean BMD) or radiographically appar-
ent vertebral by fractures, were enrolled into 2 study
groups and then randomly assigned to 1 of 3 treatment
groups. Study group 1 included those whose femoral
neck or lumbar spine BMD T-score was below −2.5.
Study group 2 included women who had low BMD and ≥1
moderate or severe vertebral fracture; low BMD and 2
mild vertebral fractures; or at least 2 moderate vertebral
fractures, regardless of BMD [13]. The MORE study
protocol was approved by the human studies review
board at each center, and informed consent was ob-
tained. The MORE clinical study was conducted accord-
ing to the ethical principles stated in the latest version of
the Declaration of Helsinki, the applicable guidelines for
good clinical practices, or the applicable laws and regula-
tions of the countries where the study was conducted,
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ual. For the current study on validity and reliability as-
sessment, the analyses included all 1477 patients who
completed the OPAQ 2.0 at baseline, and for responsive-
ness analyses, patients who completed baseline and ≥1
annual post-baseline measure (up to 36 months) were in-
cluded (Figure 1).
Clinical and health-related quality of life measurements
Participants underwent spine radiography at baseline, 24
months, and 36 months. Women were seen every 6
months over the 3 years of the MORE study. All vertebral
fractures were confirmed by review of spine radiographs,
and patients were informed of the results. Incident verte-
bral fractures were assessed at scheduled yearly follow-
up visits or at unscheduled visits, according to reported
symptoms suggestive of a fracture, but fractures were
always confirmed by radiographic evidence. Nonvertebral
fractures were determined by direct questioning, every 6
months at each clinic visit. Spine and femoral neck BMD
were measured at baseline and annually by dual-energy x-
ray absorptiometry. Nonvertebral fractures (i.e. humerus,
wrist, hip, patella, tibia/fibula, ankle, metatarsal, rib/ster-
num, clavicle, scapula, sacrum, and pelvis) were assessed
by self-report. Demographic and patient characteristics
were collected at baseline. The OPAQ 2.0 (osteoporosis-
specific HRQoL questionnaire) was administered at
baseline and annually, alongside a generic measure ofFigure 1 Population of women included in the validity and
reliability assessment and the responsiveness analysis.
Abbreviation: N = number; OPAQ = Osteoporosis Assessment
Questionnaire.quality of life (Nottingham Health Profile [NHP]) and a
preference-based measure (Health Utilities Index [HUI]).
OPAQ version 2.0
The OPAQ 2.0 is a validated, self-administered HRQoL in-
strument that consists of 67 questions (Additional file 1). It
contains 6 questions about general health, overall HRQoL,
and current living situation; 12 questions about importance
of daily activity; and 49 questions in 14 osteoporosis-
targeted domains, which yielded 4 composite dimensions
when combined through factor analyses (Additional file 2):
physical function, emotional status, symptoms, and social
interaction. The physical function dimension includes 6
domains: walking/bending, standing/sitting, dressing/
reaching, household/self-care, transfers, and usual work.
The emotional status dimension includes 4 domains: fear
of falls, level of tension, body image, and independence.
The symptoms dimension includes 2 domains: back pain
and fatigue. The social interaction dimension includes 2
domains: social activity and support of family and friends.
Measurement properties of the 4 composite dimensions
have been reported previously [6].
The developer’s scoring algorithms for the OPAQ 2.0
are described below [9,10]).
1. Selecting individual questions: A total of 48
questions (Questions 7 through 55) are used to
create 14 OPAQ domains. All 48 questions take on
values 1, 2, 3, 4, or 5.
2. Recoding: Because the OPAQ 2.0 is scored such that
a high value indicates better health status, it was
necessary to recode several items before calculating
domain and dimension scores to avoid systematic
response biases. Thus, 17 of the 48 questions were
reverse-scored so that a response of 5 indicates the
best possible quality of life, and 1 indicates the worst
quality of life. For the remaining items, 1 indicated
the best possible quality of life and 5 indicated the
worst quality of life.
3. Imputing missing data: A missing value was imputed
only if at least one-half of the questions, within the
same domain, were answered. If so, the missing
value was replaced by the average of the nonmissing
values in the same scale.
4. Forming a domain score: Values within the same
domain were added to form a domain score. If more
than one-half of the question responses were missing,
the domain score was set to missing.
5. Transformation of domain scores: All domain scores
were transformed to a range of 0 to 100, with 100
indicating the best HRQoL.
The NHP and HUI were scored according to the user
manuals. The NHP domain scores range from 0 to 100,
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ter quality of life) [18]. The HUI scores range from 0 to 1,
with higher scores indicating better health utility [19]. Both
NHP and HUI have previously been validated [18,19].
Statistical analyses
Psychometric properties of the OPAQ 2.0 domains were
evaluated by standard statistical techniques. Internal
consistency reliability was assessed by Cronbach's alpha
(>0.7 was considered acceptable) [20].
Construct validity was tested in 2 ways. First, convergent
validity between OPAQ 2.0 domains and corresponding
NHP domains and HUI scores were examined by use of
Pearson’s correlation coefficient. Correlations, which dem-
onstrate validity, typically range from 0.30 to 0.80 [21].
We hypothesized that the OPAQ 2.0 domain scores would
be significantly and meaningfully associated with corre-
sponding NHP domains and HUI scores (e.g. OPAQ 2.0
walking/bending vs. NHP mobility, and OPAQ 2.0 back
pain vs. NHP pain). By use of a criterion suggested by
Guilford and Fruchter [21], a significant correlation coeffi-
cient ≤ -0.30 or ≥0.30 [absolute value], between the OPAQ
2.0 domain and corresponding NHP domain and HUI
score was considered meaningful (i.e. supportive of the
construct validity of the OPAQ 2.0). Second, discriminant
validity was assessed by comparing OPAQ 2.0 domain
scores between several known groups by using analysis of
covariance with country of origin, age, body mass index
(BMI), years since menopause, smoking status (yes vs. no),
alcohol consumption (yes vs. no), and number of preexist-
ing conditions included in the model:
1. Presence of prevalent vertebral fracture (0 vs. ≥1, 0–1
vs. ≥2, and 0 vs. ≥2) [6,14].
2. Presence of prevalent osteoporotic nonvertebral
fracture (0 vs. ≥1 and 0–1 vs. >1) [22]. Nonvertebral
fractures included 12 locations: humerus, wrist, hip,
patella, tibia/fibula, ankle, metatarsal, rib/sternum,
clavicle, scapula, sacrum, and pelvis.
3. Trend analysis for age (<65, 65 ≤ age ≤70, and >70) [23].
4. Baseline femoral neck BMD T-scores (≥ −2.5 vs. < −2.5)
[24].
In each of the known groups above, we hypothesized
that OPAQ 2.0 domain scores would be lower for the
former group when compared to those of the latter
group. An additional analysis was performed, by using
multiple linear regression models, to examine the differ-
ences in OPAQ 2.0 domain scores with an increasing
number of prevalent vertebral fractures.
Mean changes in OPAQ 2.0 domains from baseline to
endpoint, were compared between patients with and with-
out incident vertebral fractures. Incident fracture is a
meaningful clinical endpoint for patients with establishedosteoporosis, and it was the primary endpoint in the
MORE study. It was hypothesized that HRQoL would
decrease among patients with incident vertebral fractures;
therefore, a HRQoL instrument with good responsiveness
would show differences between those patients who have
incident fractures versus those who do not. Responsive-
ness (i.e. sensitivity to clinical change) was assessed by
comparing OPAQ 2.0 score change from baseline to study
endpoint between patients with and without incident ver-
tebral fractures, by using ANCOVA adjusted for country
of origin.
Results
The demographic and clinical characteristics of partici-
pants are shown in Table 1. The 1477 women were pre-
dominantly white (96%) with a mean (standard deviation)
age of 68.4 (6.8) years. Prevalent vertebral fractures were
found in 70% (n =1038) of women; the mean (standard
deviation) number of prevalent vertebral fractures (40 days
before baseline) was 1.32 (1.38).
Table 2 summarizes baseline distribution of scores and
Cronbach’s alpha for each OPAQ 2.0 domain. The internal
consistency of 9 domains were acceptable (Cronbach’s al-
phas >0.7) and 4 domains had Cronbach’s alphas between
0.6 and 0.7 (dressing/reaching [0.68], household/self-care
[0.61], fatigue [0.68], and social activity [0.66]).
As expected, correlations were moderate and significant
for similar OPAQ 2.0 domains and NHP domains and
HUI scores. Table 3 provides a comprehensive summary
of correlations between OPAQ 2.0 and the other 2 instru-
ments (NHP and HUI). All correlations between OPAQ
2.0 and NHP were negative, which indicates that better
HRQoL measured by OPAQ 2.0 was correlated with lower
levels of distress measured by NHP. Correlations for
OPAQ 2.0 walking/bending versus NHP physical mobility
(r = −0.744) and OPAQ 2.0 back pain versus NHP pain
(r = −0.669) were substantial. Correlations between OPAQ
2.0 and HUI were positive, which indicates better HRQoL
measured by OPAQ 2.0 was correlated with high utility
score measured by HUI. Correlations between all NHP
domains and the OPAQ 2.0 domain for body image
were < |0.35| and were statistically significant (p <0.0001).
Correlations between the NHP domains and OPAQ 2.0
domains social activity (NHP physical mobility r = −0.094,
NHP pain r = −0.075, NHP sleep r = −0.089; p <0.05) and
support of family and friends (NHP physical mobility
r = −0.096, NHP pain r = −0.093; p <0.05) were < |0.35|
and were statistically significant. Similarly, correlations be-
tween HUI scores and OPAQ 2.0 domains were <0.3 for
body image (r =0.266, p <0.0001), social activity (r =0.115,
p <0.05), and support of family and friends (r =0.093,
p <0.05).
All but 2 OPAQ 2.0 domains (level of tension and sup-
port of family and friends) were able to discriminate
Table 1 Demographic and clinical characteristics
Parameter Value
Sample size, N 1477
Age, years, mean (SD) 68.42 (6.81)
Body mass index, kg/cm2, mean (SD) 25.73 (4.34)
Years postmenopause, mean (SD) 20.94 (8.65)
Racial origin, white, n (%) 1417 (96%)
Prevalent vertebral fracturea, n (%) 1038 (70%)
Femoral neck BMD T-scores, mean (SD),
[min, max]
−2.39 (0.57), [−4.5, 0.03]
Country of origin, n (%)
Australia 63 (4.3%)
Canada 116 (7.9%)
New Zealand 21 (1.4%)
United States 1277 (86%)
Smoking statusa (yes vs. no, n) 180 vs. 1271
Alcohol consumption (yes vs. no, n) 306 vs. 1171
Number of prevalent vertebral fracturea
Mean (SD) 1.32 (1.38)
>Zero vs. zero 1038 vs. 439
Number of osteoporotic nonvertebral
fracture
Mean (SD) 0.98 (1.24)
>Zero vs. zero 797 vs. 680




Family history of osteoporosis (yes vs.
no/unknown)
469 vs. 1008
History of hysterectomy (yes vs. no, n) 411 vs. 1066
Marital statusa (married vs. other, n) 823 vs. 648
Years of education, mean (SD) 13.81 (3.03)
Number of preexisting conditions, mean (SD) 10.37 (5.92)
Abbreviations: BMD = bone mineral density; min =minimum; max =maximum;
n/N = number; SD = standard deviation; vs. = versus.
aTwenty-six subjects had no record of smoking status; six subjects had no
record of marital status; three subjects had no record regarding number of
prevalent vertebral fracture.
Table 2 Baseline distribution and internal consistency of
OPAQ scales
OPAQ Scales N Mean SD Min Max Cronbach’s
Alpha
Walking/bending 1471 84.24 18.0 4 100 0.82
Standing/sitting 1472 78.71 22.2 0 100 0.73
Dressing/reaching 1471 92.05 16.4 0 100 0.68
Household/self-care 1469 91.58 14.9 13 100 0.61
Transfers 1468 90.18 19.0 0 100 0.88
Usual work 1471 90.52 18.1 0 100 N/A
Fear of falls 1473 71.86 20.8 0 100 0.82
Level of tension 1469 66.95 18.0 10 100 0.90
Body image 1468 64.56 25.9 0 100 0.76
Independence 1469 82.75 17.8 0 100 0.71
Back pain 1475 71.72 24.6 0 100 0.86
Fatigue 1472 61.82 19.6 0 100 0.68
Social activity 1470 40.17 19.4 0 100 0.66
Support, family and
friends
1469 85.06 20.8 0 100 0.78
Abbreviations: N/A = not applicable, the scale of Usual Work only has one
OPAQ item 44; OPAQ =Osteoporosis Assessment Questionnaire;
SD = standard deviation.
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fractures and were associated with a worsening trend
with increased number of vertebral fractures (Table 4).
Table 5 provides results related to discriminant validity,
against specific known groups. For presence of prevalent
osteoporotic nonvertebral fracture (0 vs. ≥1), 3 out of the
14 domains reached statistical significance (household/
self-care, transfers, and fear of falls). When 0–1 versus >1
osteoporotic nonvertebral fractures were compared, 7 of
the 14 domains reached statistical significance (walking/
bending, standing/sitting, household/self-care, transfers,
fear of falls, back pain, and fatigue), and these 7 OPAQ 2.0
domains were able to detect a linear trend. For femoralneck BMD T-scores (≥ −2.5 vs. < −2.5), 6 domains (walk-
ing/bending, dressing/reaching, household/self-care, usual
work, fear of falls, and independence) were statistically
significant (p <0.05 or p <0.001). Overall, older patients
had lower HRQoL, 7 domains (household/self-care, fear of
falls, level of tension, independence, fatigue, social activity,
and support of family and friends) for <65, 65 ≤ age ≤70,
and >70 detected a linear trend, while 4 domains (walk-
ing/bending, standing/sitting, household/self-care, and
transfers) reached statistical significance (Table 6).
Table 7 provides results related to responsiveness to
clinical changes (i.e. incident vertebral fractures). Women
with ≥1 incident vertebral fracture generally had a greater
loss in HRQoL (excluding social activity and support of
family and friends) from baseline to study endpoint, com-
pared with women without incident vertebral fractures.
There were statistically significant differences in the mean
change from baseline to study endpoint, between the 2
groups, in walking/bending (p <0.05), standing/sitting
(p <0.05), household/self-care (p <0.001), transfers (p <0.05),
usual work (p <0.05), level of tension (p <0.05), independ-
ence (p <0.05), and back pain (p <0.001); however, 6 do-
mains (dressing/reaching, fear of falls, body image, fatigue,
social activity, and support of family and friends) did not
reach statistical significant differences.
Discussion
The study assessed the reliability, construct validity, and re-
sponsiveness of the OPAQ 2.0 in a subset of women from
the MORE study population. The internal consistency
Table 3 Convergent validity: association between OPAQ, HUI, and NHP scales













Walking/bending −0.318 −0.567 −0.744 −0.609 −0.321 −0.226 0.525
Standing/sitting −0.293 −0.524 −0.710 −0.667 −0.308 −0.196 0.491
Dressing/reaching −0.211 −0.369 −0.567 −0.435 −0.213 −0.166 0.326
Household/self-care −0.189 −0.380 −0.569 −0.441 −0.194 −0.171 0.336
Transfers −0.254 −0.453 −0.679 −0.598 −0.279 −0.178 0.417
Usual work −0.294 −0.509 −0.554 −0.468 −0.287 −0.230 0.401
Fear of falls −0.352 −0.462 −0.607 −0.459 −0.304 −0.209 0.456
Level of tension −0.587 −0.434 −0.312 −0.279 −0.378 −0.349 0.341
Body image −0.249 −0.307 −0.319 −0.290 −0.227 −0.153 0.266
Independence −0.304 −0.453 −0.571 −0.444 −0.289 −0.230 0.403
Back pain −0.294 −0.493 −0.648 −0.669 −0.335 −0.173 0.496
Fatigue −0.407 −0.607 −0.476 −0.455 −0.481 −0.246 0.443
Social activity −0.156 −0.148 −0.094* −0.075* −0.089* −0.214 0.115*
Support, family and
friends
−0.293 −0.171 −0.096* −0.093* −0.105 −0.305 0.093*
Abbreviations: HUI = Health Utilities Index; NHP = Nottingham Health Profile; OPAQ = Osteoporosis Assessment Questionnaire.
Values shown are Pearson correlation coefficients.
*p <0.05; All other p-values <0.0001.
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domains, and construct validity was demonstrated by using
convergent and discriminant analyses. Domains with good
psychometric properties included walking/bending, standing/
sitting, household/self-care, transfers, usual work, fear of
falls, independence, and back pain. Domains with borderlineTable 4 Discriminative properties with respect to prevalent v
OPAQ Scales Mean Number of Prevalent Vertebral
0 (n =436) 1 (n =563) 2 (n =257) 3 (n =10
Walking/bending 87.78 85.12 83.68 78.37
Standing/sitting 85.20 79.12 76.78 70.87
Dressing/reaching 93.60 92.93 91.93 87.75
Household/self-care 94.63 92.28 89.84 86.94
Transfers 93.55 90.15 90.60 82.84
Usual work 93.92 91.29 89.26 86.39
Fear of falls 76.51 72.36 70.38 64.47
Level of tension 65.60 68.63 66.94 64.33
Body image 68.95 64.51 63.48 59.42
Independence 86.41 83.26 81.20 77.02
Back pain 78.92 71.97 69.72 61.60
Fatigue 63.62 62.34 61.33 56.19
Social activity 39.69 41.12 38.28 39.71
Support, family and friends 83.58 85.51 84.55 89.09
Abbreviations: n = number; OPAQ = Osteoporosis Assessment Questionnaire; vs. = ve
*p <0.05; **p <0.001; ***p <0.0001.
ap-values for linear trend based on analysis of covariance model controlling for cou
status (yes vs. no), alcohol consumption (yes vs. no), and number of preexisting con
bp-values based on analysis of covariance model controlling for country of origin, a
alcohol consumption (yes vs. no), and number of preexisting conditions.psychometric properties included fatigue and social activity.
Domains lacking good psychometric properties included
dressing/reaching, level of tension, body image, and support
of family and friends.
Previous versions of the OPAQ were tested in small
populations (N =40), and the results suggested that OPAQertebral fractures
Fractures p-value
2) ≥ 4 (n =116) Linear Trenda 0 vs. ≥1b 0-1 vs. ≥2 0 vs. ≥2
72.82 <0.0001*** 0.0054* <0.0001*** <0.0001***
63.15 <0.0001*** <0.0001*** <0.0001*** <0.0001***
85.78 <0.0001*** 0.4923 0.0030* 0.0557
84.48 <0.0001*** 0.0076* <0.0001*** <.00001***
83.03 <0.0001*** 0.0030* 0.0012* 0.0002**
80.22 <0.0001*** 0.0078* <0.0001*** 0.0002**
61.47 <0.0001*** 0.0030* <0.0001*** <.00001***
66.38 0.3084 0.0604 0.1486 0.8017
54.89 <0.0001*** 0.0005** 0.0006** 0.0003**
74.78 <0.0001*** 0.0026* <0.0001*** <0.0001***
56.61 <0.0001*** <0.0001*** <0.0001*** <0.0001***
58.26 0.0005** 0.1631 0.0054* 0.0141*
41.59 0.0060* 0.5474 0.0030* 0.0468*
85.67 0.4562 0.2150 0.6822 0.4006
rsus.
ntry of origin, age, body mass index (BMI), years since menopause, smoking
ditions.
ge, body mass index (BMI), years since menopause, smoking status (yes vs. no),
Table 5 Discriminative properties with prevalent osteoporotic nonvertebral fracture and femoral neck BMD





















Walking/bending 85.66 83.03 0.0645 85.29 81.22 0.0187* 0.0109* 84.90 83.23 0.0009**
Standing/sitting 80.10 77.53 0.1900 79.95 75.18 0.0363* 0.0219* 79.32 77.79 0.0591
Dressing/reaching 92.66 91.52 0.7054 92.15 91.75 0.4842 0.9948 92.69 91.07 0.0292*
Household/self-care 93.33 90.08 0.0025* 92.40 89.24 0.0422* 0.0076* 92.73 89.83 0.0014*
Transfers 92.23 88.43 0.0038* 91.56 86.20 0.0004** 0.0011* 89.96 90.51 0.4672
Usual work 91.65 89.55 0.2040 91.28 88.32 0.1198 0.1692 91.64 88.81 0.0030*
Fear of falls 74.87 69.28 <0.0001*** 73.89 66.03 <0.0001*** <0.0001*** 73.02 70.09 0.0061*
Level of tension 67.00 66.91 0.8235 67.17 66.34 0.6539 0.8418 66.90 67.04 0.9125
Body image 65.43 63.82 0.4723 65.46 62.00 0.1254 0.2605 64.41 64.79 0.8934
Independence 83.91 81.76 0.2340 83.44 80.76 0.2742 0.0605 84.01 80.83 0.0040*
Back pain 73.55 70.17 0.0544 73.26 67.31 0.0065* 0.0045* 72.25 70.92 0.1295
Fatigue 62.89 60.91 0.1529 62.71 59.28 0.0291* 0.0343* 62.04 61.49 0.2692
Social activity 39.73 40.54 0.9755 39.90 40.95 0.9519 0.5441 40.43 39.78 0.1497
Support, family and
friends
84.49 85.55 0.5963 84.85 85.66 0.6097 0.4871 84.81 85.44 0.8636
Abbreviations: BMD = bone mineral density; n = number; OPAQ =Osteoporosis Assessment Questionnaire; vs. = versus.
a,bp-values based on analysis of covariance model controlling for country of origin, age, body mass index (BMI), years since menopause, smoking status (yes vs. no),
alcohol consumption (yes vs. no), and number of preexisting conditions.
*p < 0.05; **p < 0.001; ***p < 0.0001.
Table 6 Discriminative properties with respect to age
Mean Age p-value
OPAQ Scales < 65 (n =427) 65 ≤ x ≤70 (n =378) > 70 (n =672) Linear Trenda p-valueb
Walking/bending 85.40 85.27 82.92 0.3982 0.0285*
Standing/sitting 80.91 79.48 76.89 0.9784 0.0393*
Dressing/reaching 93.81 92.58 90.64 0.1771 0.2491
Household/self-care 94.00 92.99 89.24 0.0285* 0.0095*
Transfers 91.29 90.52 89.28 0.4317 0.0111*
Usual work 92.73 91.47 88.58 0.7529 0.4834
Fear of falls 77.54 72.13 68.08 <0.0001*** 0.3762
Level of tension 63.95 67.63 68.49 <0.0001*** 0.6880
Body image 65.74 66.89 62.50 0.6496 0.0966
Independence 85.59 83.56 80.49 0.0029* 0.2028
Back pain 74.69 71.91 69.73 0.7442 0.0922
Fatigue 61.35 61.90 62.07 0.0016* 0.9252
Social activity 39.44 39.79 40.85 0.0034* 0.6037
Support, family and friends 82.57 85.42 86.44 <0.0001*** 0.6565
Abbreviations: n = number; OPAQ = Osteoporosis Assessment Questionnaire.
*p < 0.05; **p < 0.001; ***p < 0.0001.
ap-values for linear trend based on analysis of covariance model controlling for country of origin, age, body mass index (BMI), years since menopause, smoking
status (yes vs. no), alcohol consumption (yes vs. no), and number of preexisting conditions.
bp-values based on analysis of covariance model controlling for country of origin, age, body mass index (BMI), years since menopause, smoking status (yes vs. no),
alcohol consumption (yes vs. no), and number of preexisting conditions.
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Table 7 Association between incident vertebral fractures
and mean change in OPAQ at endpoint






Walking/bending −1.33 ± 14.49 −5.22 ± 20.92 0.0071*
Standing/sitting 0.47 ± 17.40 −3.30 ± 22.35 0.0165*
Dressing/reaching −1.19 ± 16.73 −3.76 ± 21.91 0.1368
Household/self-
care
−0.90 ± 14.47 −5.42 ± 19.28 0.0012*
Transfers −0.29 ± 15.53 −3.45 ± 26.57 0.0489*
Usual work −1.12 ± 17.01 −6.09 ± 25.73 0.0011*
Fear of falls −3.00 ± 15.72 −3.90 ± 19.23 0.4339
Level of tension 0.96 ± 14.86 −1.78 ± 14.23 0.0449*
Body image −0.51 ± 22.01 −1.51 ± 25.67 0.8436
Independence −0.30 ± 14.96 −4.49 ± 19.72 0.0032*
Back pain 0.71 ± 18.76 −5.60 ± 25.46 0.0004**
Fatigue 1.11 ± 16.13 −0.33 ± 14.95 0.1862
Social activity 3.68 ± 19.84 3.19 ± 19.53 0.9628
Support, family
and friends
−0.01 ± 18.04 0.90 ± 19.46 0.4000
Abbreviations: n = number; OPAQ = Osteoporosis Assessment Questionnaire.
Results are shown as the mean ± standard deviation change from baseline to
study endpoint.
a p-values based on analysis of covariance model controlling for country of
origin, age, body mass index (BMI), years since menopause, smoking status
(yes vs. no), alcohol consumption (yes vs. no), and number of
preexisting conditions.
*p < 0.05; **p < 0.001.
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distinguishing hierarchy of functional loss in disease states
in osteoporosis [9]. This study found similar results in a
larger multicenter international population of post-
menopausal women. Payers are increasingly insisting on
economic evaluations, such as cost-effectiveness analyses
and cost-utility analyses (which rely on health utility
assessment) for new treatments to support reimbursement
decisions. In studies in which utility scores are not
collected, given the high correlation between HRQoL and
utility, one would expect that improvement in HRQoL
may be reflected in improvements in health utility, which
could aid in cost-effectiveness assessment.
The HRQoL measures are more commonly included as
an outcome measure alongside BMD measurements and
the assessment of vertebral fracture incidence [14,17].
Because sudden changes in HRQoL may reflect changes
in the progression of disease (e.g. subsequent fractures)
and given that osteoporosis is a silent disease, (e.g. verte-
bral fractures or deformities may go undiagnosed and risk
for fractures can still occur with a normal BMD [25]),
detecting the worsening of disease early is important to
manage treatment success and to avoid further conse-
quences (e.g. hip fracture).All but 2 OPAQ domains—level of tension and support
of family and friends—were able to discriminate between
patients with or without prevalent vertebral fractures and
to detect a reduced HRQoL with increased number of ver-
tebral fractures. Similar results were previously reported
with the OPAQ, the Quality-of-life questionnaire of the
European Foundation for Osteoporosis (QUALEFFO), and
the geriatric depression scale [6,14,15]. However, results
differed in that no significant associations were seen in the
social interaction domains in OPAQ 2.0, which could be
due to differences between the OPAQ 2.0 and QUALEFFO.
For osteoporotic nonvertebral fractures, OPAQ 2.0 was
better able to detect a reduced HRQoL and to discriminate
between patients with 0 to 1 versus >1 nonvertebral frac-
tures—where 7 of 14 domains were statistically significant
and also were associated with a worsening trend with
increased number of vertebral fractures—than for patients
with 0 versus ≥1 fracture—where only 3 domains (house-
hold/self-care, transfers, and fear of falls) reached statistical
significance. Most of the domains that did not show statis-
tical significance are not reflective of one’s individual phys-
ical ability; they are mostly influenced by the support of
external parties. Several studies have shown an adverse
impact in HRQoL (mostly in the physical function, emo-
tional status, and symptoms dimensions) with nonvertebral
fractures; however, different instruments were used to
measure HRQoL, and our study uniquely assessed vertebral
and nonvertebral fractures separately, whereas other studies
did not [22,26-28].
For femoral neck BMD T-scores, most domains did
not discriminate well. This result could be because a
BMD of ≤ −2.5 may not fully represent the impact of
severe osteoporosis. Patients with BMD measurements
above the osteoporosis threshold of −2.5 still report frac-
tures. In the National Osteoporosis Risk Assessment
study, postmenopausal women with BMD ≤ −2.5 had the
highest rate of fractures (18% of osteoporotic fractures
and 26% of hip fractures); however, approximately 23%
of women had a BMD ≤ −2.0 or ≤ −1.5 with 1 or more
clinical risk factors, and though fracture rates were
lower, 45% of osteoporotic fractures and 53% of hip
fractures occurred in these women [29]. Most people do
not know their BMD is ≤2.5 until after a BMD test is
performed; however, most quality of life domain scores
begin to separate quickly between low BMD groups, if a
fracture has occurred.
Overall, older patients had lower HRQoL. Fractures
are often undiagnosed, and 1 study revealed that osteo-
porosis or vertebral fracture was diagnosed in <2% of
white women ≥60 years old, but the prevalence of these
fractures has been found to be 20% to 30% in these
women [30]. Osteoporotic fractures generally affect
older patients. Vertebral, hip, and wrist fractures are pri-
mary causes for morbidity in patients with osteoporosis,
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function [4,31-34]. These fractures, in turn, can lead to
lower quality of life, so these results are not surprising;
however, decreasing HRQoL in older patients could also
be explained by additional chronic illnesses, comorbidi-
ties, and a number of other factors.
Women with ≥1 incident vertebral fracture generally had
a greater loss in HRQoL from baseline to study endpoint,
compared with women without incident vertebral fractures,
which is consistent with previous research [6,26,27].
There are some important limitations that should be
considered when interpreting these findings. This study
was a post hoc retrospective analysis. Although the study
used data from the MORE study—which was a well-
controlled randomized clinical trial with a large, heteroge-
neous osteoporosis patient population and included
multiple HRQoL instruments (including generic, disease-
specific, and preference-based instruments)—the trial was
conducted in the 1990s and some results may not be as
generalizable today. We also were unable to conduct a
time to event analysis on HRQoL scores between baseline
and the time of vertebral fracture due to the timing of
vertebral fracture assessments (baseline, and months 12,
24 and 36).
This study assessed the psychometric properties of the
OPAQ at the domain level, whereas previous work focused
attention on the dimension level [6,10,14]. Results from the
current study are consistent with previous research; how-
ever, domain-level results have not been disclosed in the
past, and for further development and validation of OPAQ
and other osteoporosis-specific instruments, domain-level
results provide useful information.
The OPAQ 2.0 is a validated, self-administered HRQoL
instrument. The OPAQ 2.0 was developed to capture
broader dimensions of HRQoL for patients with osteo-
porosis in clinical trials; however, the length of the original
version of OPAQ 2.0 (67 questions) and the resulting re-
spondent time burden could pose a concern for inclusion
in clinical trials. Our findings suggest that there are
domains that could be reassessed to further refine OPAQ
2.0 to develop a shorter version that has the best psycho-
metric properties for use in clinical trials and routine
patient care that follow recent United States Food and
Drug Administration guidelines.
Conclusions
Most of the domains in the 67-item OPAQ instrument
(version 2.0) have demonstrated reliability, discriminant
validity, and responsiveness. Despite these robust find-
ings, there is a need in clinical trial research to limit the
number of items to as few as possible and to minimize
patient responder burden. The findings provided here
suggest that there are several domains that do not show
these criteria and that may need to be reassessed andremoved for a potentially shorter and validated version
of OPAQ.
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